Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Outcomes of classic HL, relapsed within one year of diagnosis, in the era of novel agents

Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, discusses outcomes of primary refractory disease and early relapse in patients with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) treated with salvage therapy and autologous stem cell transplant (ASCT). Patients who relapsed within 1 year of diagnosis were highly likely to receive more than one line of salvage regimen before stem cell transplant, and they were less likely to be successfully bridged after 1 line of salvage therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.